natgillin/translations-raw huggingface dataset:
Under administration af ofatumumab skal patienten monitoreres tæt for tegn på infusionsreaktioner, herunder cytokinfrigivelsessyndrom, særligt under den første infusion.
Patients should be closely monitored during administration of ofatumumab for the onset of infusion reactions, including cytokine release syndrome, particularly during the first infusion.
Under alle kliniske studier med NovoEight blev der i alt reporteret 30 bivirkninger hos 19 af de 214 patienter eksponeret for NovoEight.
During all clinical studies with NovoEight, a total of 30 adverse reactions were reported in 19 of 214 patients exposed to NovoEight.
Under amning.
During breast feeding.
Under antipsykotisk behandling kan bedring i patientens kliniske tilstand vare fra flere dage til nogle uger.
During antipsychotic treatment, improvement in the patient’s clinical condition may take several days to some weeks.
Under antipsykotisk behandling kan det tage flere dage eller nogle uger før patientens kliniske tilstand bedres.
During antipsychotic treatment, improvement in the patient's clinical condition may take several days to some weeks.
Under anvendelse af aseptisk overførselsteknik udtages med hver 3 ml sprøjte med kanyle 1,4 ml af det rekonstituerede hætteglas med dibotermin alfa (rhBMP-2) i det ikke-sterile område.
Using aseptic transfer technique and for each 3 ml syringe with needle, withdraw 1.4 ml from the reconstituted vial of dibotermin alfa (rhBMP-2) in the non-sterile field.
Under anvendelse af en aseptisk teknik, skal Rilonacept Regeneron-pulveret rekonstitueres med 2,3 ml solvens (vand til injektionsvæske) før administration.
Using aseptic technique, Rilonacept Regeneron powder should be reconstituted with 2.3 ml of solvent (water for injections) prior to administration.
Under anvendelsen efter markedsføringen er der modtaget isolerede indberetninger, der peger på ikke-infektiøs hepatitis.
During post-marketing use isolated case reports indicating non-infectious hepatitis have been received.
Under anvendelsen kan du tage Rebif ud af køleskabet og opbevare den ved temperaturer ikke over 25 °C i en enkelt periode på op til 14 dage.
For the purpose of ambulatory use, you may remove Rebif from the refrigerator and store it not above 25°C for one single period of up to 14 days.
Under anæstesivedligeholdelse vil øgning af sevofluran koncentrationen bevirke et dosisafhængigt blodtryksfald.
During maintenance of anaesthesia, increasing the concentration of sevoflurane produces a dose dependent decrease in blood pressure.
Under anæstesivedligeholdelse vil øgning af sevofluran koncentrationen bevirke et dosisafhængigt blodtryksfald.
During maintenance of anaesthesia, increasing the concentration of sevoflurane produces a dose- dependent decrease in blood pressure.
Under aseptisk teknik løftes et lille stykke skind i hundens umbilicus region og der injiceres subkutant. (Fig.
Using aseptic technique, raise a small piece of skin in the region of the dog’s umbilicus.
Under aseptisk teknik løftes et lille stykke skind i hundens umbilikale region, og der injiceres subkutant.
Using aseptic technique, raise a small piece of skin in the region of the dogs umbilicus.
Under aseptiske forhold overføres den beregnede mængde ramucirumab til den tomme intravenøse infusionsbeholder.
Aseptically transfer the calculated volume of ramucirumab into an empty intravenous infusion container.
Under aseptiske forhold rekonstitueres hvert Inflectra-hætteglas med 10 ml vand til i injektionsvæsker ved hjælp af en sprøjte med en gauge 21 (0,8 mm) nål eller med en mindre nål.
Under aseptic conditions, each Inflectra vial should be reconstituted with 10 mL of water for injections, using a syringe equipped with a 21-gauge (0.8 mm) or smaller needle.
Under aseptiske forhold rekonstitueres hvert Inflectra-hætteglas med 10 ml vand til injektionsvæsker ved hjælp af en sprøjte med en gauge 21 (0,8 mm) nål eller med en mindre nål.
Under aseptic conditions, each Inflectra vial should be reconstituted with 10 mL of water for injections, using a syringe equipped with a 21-gauge (0.8 mm) or smaller needle.
Under aseptiske forhold rekonstitueres hvert Remsima-hætteglas med 10 ml vand til i injektionsvæsker ved hjælp af en sprøjte med en gauge 21 (0,8 mm) nål eller med en mindre nål.
Under aseptic conditions, each Remsima vial should be reconstituted with 10 mL of water for injections, using a syringe equipped with a 21-gauge (0.8 mm) or smaller needle.
Under aseptiske forhold rekonstitueres hvert Remsima-hætteglas med 10 ml vand til injektionsvæsker ved hjælp af en sprøjte med en gauge 21 (0,8 mm) nål eller med en mindre nål.
Under aseptic conditions, each Remsima vial should be reconstituted with 10 mL of water for injections, using a syringe equipped with a 21-gauge (0.8 mm) or smaller needle.
Under behandling af voksne og unge med Voncento kan der opstå følgende bivirkninger: Overfølsomhed eller allergiske reaktioner, tromboemboliske hændelser, pyreksi, hovedpine, dysgeusi og anormale værdier i leverfunktionsprøver.
During treatment with Voncento in adults and adolescents the following adverse reactions may occur: Hypersensitivity or allergic reactions, thromboembolic events, pyrexia, headache, dysgeusia and abnormal liver function test levels.
Under behandling bør nyrefunktionen vurderes i kliniske situationer, hvor der er mistanke om et fald i nyrefunktionen (f.eks. hypovolæmi, dehydrering og samtidig behandling med visse typer anden medicin) (se pkt 4.3,4.4 og 5.2).
While on treatment the renal function should also be assessed in certain clinical situations when it is suspected that the renal function could decline or deteriorate (such as hypovolemia, dehydration, and with certain comedications, etc) (see sections 4.3, 4.4 and 5.2).
Under behandling med Atosiban SUN vil dine sammentrækninger og dit ufødte barns puls sandsynligvis blive overvåget.
During treatment with Atosiban SUN, your contractions and your unborn baby’s heart rate may be monitored.
Under behandling med belatacept kan vaccinationer derfor være mindre effektive, om end dette dog ikke er blevet undersøgt i kliniske forsøg.
Therefore, during treatment with belatacept, vaccinations may be less effective although this has not been studied in clinical trials.
Under behandling med betablokkere kan patienter med en anamnesemed atopi eller svære anafylaktiske reaktioner over for en række allergener være mere reaktive over for gentagen udsættelse for sådanne allergener og risikere ikke at respondere på normale doser af adrenalin til behandling af anafylaktiske reaktioner.
While taking beta-blockers, patients with history of atopy or a history of severe anaphylactic reaction to a variety of allergens may be more reactive to repeated challenge with such allergens and unresponsive to the usual dose of adrenaline used to treat anaphylactic reactions.
Under behandling med BiResp Spiromax kan der forekomme alvorlige astmarelaterede bivirkninger og eksacerbationer.
Serious asthma-related adverse reactions and exacerbations may occur during treatment with BiResp Spiromax.
Under behandling med Brintellix kan der forekomme serotonergt syndrom eller malignt neuroleptikasyndrom, som er potentielt livstruende tilstande.
Serotonin Syndrome (SS) or Neuroleptic Malignant Syndrome (NMS), potentially life-threatening conditions, may occur with Brintellix.
Under behandling med Budesonid/Formoterol Teva kan der forekomme alvorlige astmarelaterede reaktioner og eksacerbationer.
Serious asthma-related adverse reactions and exacerbations may occur during treatment with Budesonide/Formoterol Teva.
Under behandling med Budesonid/Formoterol Teva Pharma B.V. kan der forekomme alvorlige astmarelaterede reaktioner og eksacerbationer.
Serious asthma-related adverse reactions and exacerbations may occur during treatment with Budesonide/Formoterol Teva Pharma B.V..
Under behandling med dette lægemiddel:
During treatment with Komboglyze:
Under behandling med dette lægemiddel:
During treatment with this medicine:
Under behandling med DuoResp Spiromax kan der forekomme alvorlige astmarelaterede bivirkninger og eksacerbationer.
Serious asthma-related adverse reactions and exacerbations may occur during treatment with DuoResp Spiromax.
Under behandling med Ebilfumin skal du omgående fortælle lægen hvis du lægger mærke til ændringer i adfærd eller humør (neuropsykiatriske hændelser), især hos børn og unge.
During treatment with Ebilfumin, tell a doctor immediately: if you notice changes in behaviour or mood (neuropsychiatric events), especially in children and adolescents.
Under behandling med eltrombopag skal det fuldstændige blodbillede (komplet blodtælling (CBC)) inklusive trombocyttal og perifer blodudstrygning vurderes ugentligt, indtil der opnås et stabilt trombocyttal (≥ 50.000 pr. µl i mindst 4 uger).
During therapy with eltrombopag full blood counts (FBCs), including platelet count and peripheral blood smears, should be assessed weekly until a stable platelet count (≥ 50,000/µl for at least 4 weeks) has been achieved.
Under behandling med enoxaparinnatrium i højere doser kan der forekomme forlængelse af aktiveret partiel tromboplastintid (APTT) og aktiveret koagulationstid (ACT).
While taking enoxaparin sodium at higher doses, prolongation of the activated partial thromboplastin time (APTT) and activated clotting time (ACT) may occur.
Under behandling med enoxaparinnatrium i højere doser kan der forekomme forlængelse af aktiveret partiell tromboplastintid (APTT) og aktiverede koagulationstid (ACT).
While taking enoxaparin sodium at higher doses, prolongation of the activated partial thromboplastin time (APTT) and activated clotting time (ACT) may occur.
Under behandling med enoxaparinnatrium i højere doser kan der forekomme forlængelse af den aktiverede partielle tromboplastintid (APTT) og aktiverede koagulationstid (ACT).
While taking enoxaparin sodium at higher doses, prolongation of the activated partial thromboplastin time (APTT) and activated clotting time (ACT) may occur.
Under behandling med Enurev Breezhaler, stop med at tage medicinen og fortæl det øjeblikkeligt til din læge: hvis du oplever trykken for brystet, hoste, hvæsen eller åndenød umiddelbart efter, du har taget Enurev Breezhaler (tegn på bronkospasme).
During treatment with Enurev Breezhaler, stop taking this medicine and tell your doctor immediately: if you experience tightness of the chest, coughing, wheezing or breathlessness immediately after using Enurev Breezhaler (signs of bronchospasm).
Under behandling med Extavia kan der opstå nyreproblemer inkl. ardannelse (glomerulosklerose), som kan nedsætte din nyrefunktion.
During treatment with Extavia, kidney problems that may reduce your kidney function, including scarring (glomerulosclerosis), may occur.
Under behandling med Extavia kan din krop producere stoffer, som kaldes neutraliserende antistoffer, som kan reagere mod Extavia.
During treatment with Extavia your body may produce substances called neutralising antibodies, which may react with Extavia.
Under behandling med Flixabi æ ndringer i dit hjerteslag.
During treatment with Flixabi
Under behandling med Hirobriz Breezhaler:
During treatment with Hirobriz Breezhaler,
Under behandling med Lynparza er der rapporteret om asteni, træthed og svimmelhed, og patienter, som oplever disse symptomer, skal udvise forsigtighed, når de fører motorkøretøj eller betjener maskiner.
During treatment with Lynparza, asthenia, fatigue, and dizziness have been reported and those patients who experience these symptoms should observe caution when driving or using machines.
Under behandling med micafungin kan anafylaktiske/anafylaktoide reaktioner forekomme, herunder anafylaktisk shock.
During administration of micafungin, anaphylactic/anaphylactoid reactions including shock may occur.
Under behandling med NeoRecormon
During treatment with NeoRecormon
Under behandling med olanzapin i kombination med lithium eller valproat forekom en stigning på 7 % af baseline legemsvægt hos 17,4 % af patienterne i akut behandling (op til 6 uger).
During treatment with olanzapine in combination with lithium or divalproex, an increase of  7 % from baseline body weight occurred in 17.4 % of patients during acute treatment (up to 6 weeks).
Under behandling med olanzapin i kombination med lithium eller valproat forekom en stigning på 7 % af baseline legemsvægt hos 17,4 % af patienterne i akut behandling (op til 6 uger).
During treatment with olanzapine in combination with lithium or divalproex, an increase of  7% from baseline body weight occurred in 17.4% of patients during acute treatment (up to 6 weeks).
Under behandling med olanzapin i kombination med lithium eller valproat forekom en stigning på 7 % fra baseline legemsvægt hos 17,4 % af patienterne i akut behandling (op til 6 uger).
During treatment with olanzapine in combination with lithium or divalproex, an increase of  7% from baseline body weight occurred in 17.4% of patients during acute treatment (up to 6 weeks).
Under behandling med olanzapin i kombination med lithium eller valproat forekom en stigning på 7% fra baseline legemsvægt hos 17,4% af patienterne i akut behandling (op til 6 uger).
During treatment with olanzapine in combination with lithium or divalproex, an increase of  7 % from baseline body weight occurred in 17.4 % of patients during acute treatment (up to 6 weeks).
Under behandling med olanzapin i kombination med lithium eller valproat forekom er stigning på 7 % af baseline legemsvægt hos 17,4 % af patienterne i akut behandling (op til 6 uger).
During treatment with olanzapine in combination with lithium or divalproex, an increase of  7% from baseline body weight occurred in 17.4% of patients during acute treatment (up to 6 weeks).
Under behandling med olanzapin i kombination med lithium eller valproat stigning på 7 % af baseline legemsvægt hos 17,4 % af patienterne i akut behandling (op til 6 uger).
During treatment with olanzapine in combination with lithium or divalproex, an increase of  7 % from baseline body weight occurred in 17.4 % of patients during acute treatment (up to 6 weeks).
Under behandling med olanzapin i kombination med lithium eller valproat stigning på 7 % af baseline legemsvægt hos 17,4 % af patienterne i akut behandling (op til 6 uger).
During treatment with olanzapine in combination with lithium or divalproex, an increase of  7% from baseline body weight occurred in 17.4% of patients during acute treatment (up to 6 weeks).
Under behandling med olanzapin i kombination med lithium eller valproat sås en stigning på 7 % af baseline legemsvægt hos 17,4 % af patienterne ved akut behandling (op til 6 uger).
During treatment with olanzapine in combination with lithium or divalproex, an increase of  7 % from baseline body weight occurred in 17.4 % of patients during acute treatment (up to 6 weeks).
Under behandling med olanzapin i kombination med lithium eller valproat sås en stigning på 7 % af baseline legemsvægt hos 17,4 % af patienterne ved akut behandling (op til 6 uger).
During treatment with olanzapine in combination with lithium or divalproex, an increase of  7% from baseline body weight occurred in 17.4% of patients during acute treatment (up to 6 weeks).
Under behandling med olanzapin sammen med lithium eller valproat forekom en stigning p å ≥ 7 % af baseline legemsvægt hos 17,4 % af patienterne ved akut behandling (op til 6 uger).
During treatment with olanzapine in combination with lithium or divalproex, an increase of ≥ 7 % from baseline body weight occurred in 17.4 % of patients during acute treatment (up to 6 weeks).
Under behandling med olanzapin sammen med lithium eller valproat forekom en stigning på ≥ 7 % af baseline legemsvægt hos 17,4 % af patienterne akut behandling (op til 6 uger).
During treatment with olanzapine in combination with lithium or divalproex, an increase of  7% from baseline body weight occurred in 17.4% of patients during acute treatment (up to 6 weeks).
Under behandling med olanzapin sammen med lithium eller valproat forekom en stigning på 7 % af baseline legemsvægt hos 17,4 % af patienterne ved akut behandling (op til 6 uger).
During treatment with olanzapine in combination with lithium or divalproex, an increase of  7 % from baseline body weight occurred in 17.4 % of patients during acute treatment (up to 6 weeks).
Under behandling med olanzapin sammen med lithium eller valproat forekom en stigning på 7 % af baseline legemsvægt hos 17,4 % af patienterne ved akut behandling (op til 6 uger).
During treatment with olanzapine in combination with lithium or divalproex, an increase of  7% from baseline body weight occurred in 17.4% of patients during acute treatment (up to 6 weeks).
Under behandling med olanzapin tog de unge signifikant mere p å i vægt sammenlignet med voksne.
During treatment with olanzapine, adolescents gained significantly more weight compared with adults.
Under behandling med olanzapin tog de unge signifikant mere på i vægt sammenlignet med voksne.
The pharmacokinetics of olanzapine are similar between adolescents and adults.
Under behandling med Pradaxa bør nyrefunktionen vurderes mindst en gang årligt eller oftere, hvis der opstår kliniske situationer med mistanke om, at der kan indtræde et fald eller en forringelse i nyrefunktionen (f.eks. hypovolæmi, dehydrering eller samtidig behandling med visse andre lægemidler)
Renal function should be assessed during treatment with Pradaxa at least once a year or more frequently as needed in certain clinical situations when it is suspected that the renal function could decline or deteriorate (e.g. hypovolaemia, dehydration, and in case of concomitant us of certain medicinal products)
Under behandling med Pradaxa bør nyrefunktionen vurderes mindst en gang årligt eller oftere, hvis der opstår kliniske situationer med mistanke om, at der kan indtræde et fald eller en forringelse i nyrefunktionen (f.eks. hypovolæmi, dehydrering eller ved samtidig behandling med visse andre lægemidler).
Renal function should be assessed during treatment with Pradaxa at least once a year or more frequently as needed in certain clinical situations when it is suspected that the renal function could decline or deteriorate (e.g. hypovolaemia, dehydration, and in case of concomitant use of certain medicinal products)
Under behandling med Ranexa
During Ranexa treatment
Under behandling med Rapamune med eller uden ciclosporin (CsA) bør patienter kontrolleres for forhøjede nivauer af lipider, og patienter, der får HMG-CoAreduktasehæmmer og/eller fibrat, bør kontrolleres for mulig udvikling af rabdomyolyse eller andre bivirkninger, som er beskrevet i de respektive produktresuméer for disse stoffer.
During Rapamune therapy with or without CsA, patients should be monitored for elevated lipids, and patients administered an HMG-CoA reductase inhibitor and/or fibrate should be monitored for the possible development of rhabdomyolysis and other adverse reactions, as described in the respective Summary of Product Characteristics of these agents.
Under behandling med Sebivo:
During the treatment with Sebivo:
Under behandling med Seebri Breezhaler, stop med at tage medicinen og fortæl det øjeblikkeligt til din læge: hvis du oplever trykken for brystet, hoste, hvæsen eller åndenød umiddelbart efter, du har taget Seebri Breezhaler (tegn på bronkospasme).
During treatment with Seebri Breezhaler, stop taking this medicine and tell your doctor immediately: if you experience tightness of the chest, coughing, wheezing or breathlessness immediately after using Seebri Breezhaler (signs of bronchospasm).
Under behandling med STAYVEER vil Deres læge sørge for regelmæssige blodprøver for at kontrollere forandringer i Deres leverfunktion og hæmoglobinniveau.
During treatment with STAYVEER, your doctor will arrange for regular blood tests to check for changes in your liver function and haemoglobin level.
Under behandling med Tamiflu skal du omgående fortælle lægen hvis du lægger mærke til ændringer i adfærd eller humør (neuropsykiatriske hændelser), især hos børn og unge.
During treatment with Tamiflu, tell a doctor immediately: if you notice changes in behaviour or mood (neuropsychiatric events), especially in children and adolescents).
Under behandling med Tasigna kan du også få unormale resultater fra blodprøver såsom lavt antal blodceller (hvide blodlegemer, røde blodlegemer og blodplader), øget indhold af lipase eller amylase (funktionen af bugspytkirtlen), øget indhold af bilirubin (leverfunktionen) eller øget indhold af kreatinin (nyrefunktionen) i blodet, lavt eller højt indhold af insulin i blodet (hormon, der regulerer blodsukkeret), lavt eller højt indhold af sukker eller højt fedt-indhold i blodet.
During Tasigna treatment, you may also have some abnormal blood test results such as low level of blood cells (white cells, red cells, platelets), high blood level of lipase or amylase (pancreas function), high blood level of bilirubin (liver function) or high blood level of creatinine (kidney function), low or high blood level of insulin (a hormone regulating blood sugar level), low or high level of sugar, or high level of fats in the blood.
Under behandling med Tovanor Breezhaler, stop med at tage medicinen og fortæl det øjeblikkeligt til din læge: hvis du oplever trykken for brystet, hoste, hvæsen eller åndenød umiddelbart efter, du har taget Tovanor Breezhaler (tegn på bronkospasme).
During treatment with Tovanor Breezhaler, stop taking this medicine and tell your doctor immediately: if you experience tightness of the chest, coughing, wheezing or breathlessness immediately after using Tovanor Breezhaler (signs of bronchospasm).
Under behandling med Tracleer vil Deres læge sørge for regelmæssige blodprøver, for at kontrollere forandringer i Deres leverfunktion og hæmoglobinniveau.
During treatment with Tracleer, your doctor will arrange for regular blood tests to check for changes in your liver function and haemoglobin level.
Under behandling med Tractocile vil dine sammentrækninger og dit ufødte barns hjertefrekvens sandsynligvis blive fulgt.
During treatment with Tractocile, your contractions and your unborn baby’s heart rate may be monitored.
Under behandling med Tractocile, vil dine sammentrækninger og dit ufødte barns hjertefrekvens sandsynligvis blive fulgt.
During treatment with Tractocile, your contractions and your unborn baby’s heart rate may be monitored.
Under behandling med Ultibro Breezhaler
During treatment with Ultibro Breezhaler
Under behandling med Ulunar Breezhaler
During treatment with Ulunar Breezhaler
Under behandling med Vistide bør du regelmæssigt få foretaget øjenundersøgelser for mulig øjenirritation, betændelse eller hævelse.
During treatment with Vistide you should receive regular follow-up eye examinations for possible eye irritation, inflammation or swelling.
Under behandling med Xoterna Breezhaler
During treatment with Xoterna Breezhaler
Under behandling og indtil ophelingen vil den angrebne hud sandsynligvis fremstå forskellig fra den normale hud.
During therapy and until healed, affected skin is likely to appear noticeably different from normal skin.
Under behandlingen anbefales det, at kvinder som kan blive gravide, anvender effektiv beskyttelse mod graviditet.
Women who might become pregnant are advised to use effective contraception during treatment.
Under behandlingen anbefales omhyggelig monitorering med EBV-PCR.
During treatment, careful monitoring with EBV-PCR is recommended.
Under behandlingen baserende på kontraceptionsmetoden
During treatment based on method of contraception
Under behandlingen baserende på præventionsmetoden
During treatment based on method of contraception
Under behandlingen bør disse patienter undersøges for kliniske, virologiske og serologiske parametre knyttet til hepatitis B, lever- og nyrefunktion og antiviralt respons (mindst hver måned) og i mindst 6 måneder efter behandlingsophør, hvis behandlingen af en eller anden grund seponeres.
These patients should be monitored for clinical, virological and serological parameters associated with hepatitis B, liver and renal function, and antiviral response during treatment (at least every month), and, if treatment is discontinued for any reason, for at least 6 months after treatment.